Rallybio Q2 EPS $(0.37) Misses $(0.33) Estimate
Portfolio Pulse from Benzinga Newsdesk
Rallybio (NASDAQ:RLYB) reported a Q2 EPS of $(0.37), missing the analyst consensus estimate of $(0.33) by 12.12%. This represents a 19.57% improvement over the $(0.46) loss per share from the same period last year.
August 08, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Rallybio reported a Q2 EPS of $(0.37), missing the analyst consensus estimate of $(0.33) by 12.12%. Despite the miss, the loss per share improved by 19.57% compared to the same period last year.
The miss on EPS estimates is likely to have a negative short-term impact on the stock price. However, the improvement in losses compared to the previous year may mitigate some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100